SteelPeak Wealth LLC Buys New Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

SteelPeak Wealth LLC purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 668 shares of the biotechnology company’s stock, valued at approximately $209,000.

Other institutional investors have also modified their holdings of the company. Trivant Custom Portfolio Group LLC acquired a new stake in Axon Enterprise during the first quarter worth about $31,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Axon Enterprise during the 1st quarter valued at approximately $392,000. AMF Tjanstepension AB lifted its stake in shares of Axon Enterprise by 26.7% in the 1st quarter. AMF Tjanstepension AB now owns 34,341 shares of the biotechnology company’s stock valued at $10,745,000 after purchasing an additional 7,233 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Axon Enterprise by 4.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,519 shares of the biotechnology company’s stock valued at $2,353,000 after buying an additional 319 shares during the period. Finally, Brookstone Capital Management increased its holdings in Axon Enterprise by 5.1% in the first quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 41 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In other news, Director Jeri Williams sold 308 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total value of $95,501.56. Following the transaction, the director now owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Jeri Williams sold 308 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the transaction, the director now directly owns 1,607 shares in the company, valued at approximately $498,282.49. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Julie A. Cullivan sold 478 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the sale, the director now owns 5,546 shares of the company’s stock, valued at approximately $1,586,377.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 89,447 shares of company stock worth $27,684,677. Company insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on AXON shares. Barclays increased their target price on shares of Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th. Morgan Stanley raised their price objective on Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, April 26th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Argus began coverage on shares of Axon Enterprise in a research note on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $335.27.

Axon Enterprise Stock Down 1.4 %

Shares of NASDAQ:AXON opened at $294.24 on Monday. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87. The stock has a market cap of $22.21 billion, a P/E ratio of 86.04 and a beta of 0.95. The business has a fifty day moving average of $295.25 and a two-hundred day moving average of $285.26. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The firm had revenue of $460.74 million during the quarter, compared to analysts’ expectations of $441.57 million. During the same period last year, the business earned $0.51 earnings per share. Axon Enterprise’s revenue was up 34.3% compared to the same quarter last year. On average, research analysts expect that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.